Cost-effectiveness of liposomal amphotericin B in hospitalised patients with mucocutaneous leishmaniasis.

摘要: Objective To compare the cost-effectiveness of L-AmB with that SbV and AmB-D, for treatment mucocutaneous leishmaniasis in a hospital northeast Brazil. Methods We developed an economic model based on retrospective data 73 hospitalized patients 2006-2012, from public health system perspectives. Results In model, 82.2% who started had completed it after 2 months, versus 22.0% 19.9% AmB-D groups. After 12 months follow-up, these proportions were 100% L-AmB, 77.4% 72.2% group. Markov chain analyses showed group therapy lowest mean total cost (US$ 3,782.38), followed by 5,211.27) 11,337.44). The incremental ratio was US$ 18,816.23 against SbV, 24,504.65 AmB-D. In sensitivity analysis, drug acquisition significantly influenced results. Conclusions In is cost-effective alternative to owing its higher effectiveness, safety, shorter course. This article protected copyright. All rights reserved.